JZP-815 is a small molecule commercialized by Jazz Pharmaceuticals, with a leading Phase I program in Hematological Tumor. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of JZP-815’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for JZP-815 is expected to reach an annual total of $19 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
JZP-815 Overview
JZP-815 is under development for the treatment of solid tumors including non-small cell lung cancer and colorectal cancer and hematological malignancies (blood cancer). It is administered through oral route in the form of capsule. It acts by targeting pan-Raf. The drug candidate is developed based on Redox Switch platform technology.
Jazz Pharmaceuticals Overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
The company reported revenues of (US Dollars) US$3,834.2 million for the fiscal year ended December 2023 (FY2023), an increase of 4.8% over FY2022. The operating profit of the company was US$578.6 million in FY2023, compared to an operating loss of US$65.5 million in FY2022. The net profit of the company was US$414.8 million in FY2023, compared to a net loss of US$224.1 million in FY2022.
The company reported revenues of US$1,023.8 million for the second quarter ended June 2024, an increase of 13.5% over the previous quarter.
For a complete picture of JZP-815’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
